DK3193931T3 - Neutralisering af hæmmende veje i lymfocytter - Google Patents

Neutralisering af hæmmende veje i lymfocytter Download PDF

Info

Publication number
DK3193931T3
DK3193931T3 DK15766120.8T DK15766120T DK3193931T3 DK 3193931 T3 DK3193931 T3 DK 3193931T3 DK 15766120 T DK15766120 T DK 15766120T DK 3193931 T3 DK3193931 T3 DK 3193931T3
Authority
DK
Denmark
Prior art keywords
lymphocyte
roads
neutralization
inhibitory
inhibitory roads
Prior art date
Application number
DK15766120.8T
Other languages
English (en)
Inventor
Pascale Andre
Mathieu Blery
Carine Paturel
Nicolaï Wagtmann
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of DK3193931T3 publication Critical patent/DK3193931T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15766120.8T 2014-09-16 2015-09-15 Neutralisering af hæmmende veje i lymfocytter DK3193931T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462050948P 2014-09-16 2014-09-16
US201462083929P 2014-11-25 2014-11-25
US201462093141P 2014-12-17 2014-12-17
PCT/EP2015/071069 WO2016041945A1 (en) 2014-09-16 2015-09-15 Neutralization of inhibitory pathways in lymphocytes

Publications (1)

Publication Number Publication Date
DK3193931T3 true DK3193931T3 (da) 2020-10-19

Family

ID=54147180

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15766120.8T DK3193931T3 (da) 2014-09-16 2015-09-15 Neutralisering af hæmmende veje i lymfocytter

Country Status (24)

Country Link
US (3) US10711063B2 (da)
EP (3) EP3193931B1 (da)
JP (2) JP6767362B2 (da)
KR (2) KR102543739B1 (da)
CN (2) CN107001466B (da)
AU (1) AU2015316991B2 (da)
BR (1) BR112017005178A2 (da)
CA (1) CA2957491A1 (da)
CY (1) CY1123827T1 (da)
DK (1) DK3193931T3 (da)
ES (1) ES2825576T3 (da)
HR (1) HRP20201656T1 (da)
HU (1) HUE051193T2 (da)
IL (1) IL250587B (da)
LT (1) LT3193931T (da)
MX (1) MX2017003303A (da)
PL (1) PL3193931T3 (da)
PT (1) PT3193931T (da)
RS (1) RS60935B1 (da)
RU (1) RU2734771C2 (da)
SG (2) SG10202008228XA (da)
SI (1) SI3193931T1 (da)
WO (1) WO2016041945A1 (da)
ZA (1) ZA201702642B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
EP2721068B1 (en) 2011-06-17 2018-12-05 Novo Nordisk A/S Selective elimination of erosive cells
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
ES2742456T3 (es) 2014-09-16 2020-02-14 Innate Pharma Regímenes de tratamiento utilizando anticuerpos anti-NKG2A
KR102543739B1 (ko) 2014-09-16 2023-06-16 이나뜨 파르마 에스.에이. 림프구에서의 억제 경로의 중화
WO2016062851A1 (en) 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
CA2990520C (en) 2015-07-24 2023-06-27 Innate Pharma Methods for detecting tissue infiltrating nk cells
CA3012055A1 (en) * 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
KR102630017B1 (ko) * 2016-07-07 2024-01-25 이오반스 바이오테라퓨틱스, 인크. 프로그램화된 사멸 1 리간드 1 (pd-l1) 결합 단백질 및 그의 사용 방법
DE102017001875A1 (de) * 2017-02-27 2018-08-30 Wolfgang Würfel Medikament zur Malignombehandlung
KR20200026254A (ko) * 2017-07-10 2020-03-10 이나뜨 파르마 암을 치료하기 위해 인간 siglec-9 에 대한 항체 및 인간 nkg2a 에 대한 항체를 사용하는 조합 치료요법
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
EP3765508A1 (en) 2018-03-13 2021-01-20 Innate Pharma Treatment of head and neck cancer
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
EP3793607A1 (en) * 2018-05-15 2021-03-24 MedImmune Limited Treatment of cancer
CN110563842B (zh) * 2018-06-06 2022-07-29 浙江博锐生物制药有限公司 针对程序性死亡配体(pd-l1)的抗体及其应用
EP3818082A1 (en) * 2018-07-04 2021-05-12 F. Hoffmann-La Roche AG Novel bispecific agonistic 4-1bb antigen binding molecules
JP7520003B2 (ja) 2018-11-16 2024-07-22 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CA3201348A1 (en) 2020-12-28 2022-07-07 Masano HUANG Antibody compositions and methods of use thereof
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CN114214430A (zh) * 2021-12-20 2022-03-22 安徽中盛溯源生物科技有限公司 Nkg2a在检测小鼠人源肿瘤模型中人nk细胞中的应用
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
EP1513554B9 (en) 2002-05-30 2011-11-09 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
BR0316880A (pt) * 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
CN104645327A (zh) * 2003-07-24 2015-05-27 依奈特制药公司 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物
CN101107269B (zh) * 2004-12-28 2012-10-31 依奈特制药公司 抗nkg2a的单克隆抗体
PT1831258E (pt) * 2004-12-28 2016-01-07 Univ Genova Anticorpos monoclonais contra nkg2a
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ES2531933T3 (es) 2006-06-30 2015-03-20 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
KR20100110864A (ko) 2008-01-24 2010-10-13 노보 노르디스크 에이/에스 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
PE20110435A1 (es) * 2008-08-25 2011-07-20 Amplimmune Inc Composiciones antagonistas del pd-1
JP6087503B2 (ja) * 2008-09-26 2017-03-08 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
PT4209510T (pt) 2008-12-09 2024-04-02 Hoffmann La Roche Anticorpos anti-pm-l1 e a sua utilização para a melhoria do funcionamento das células t
MX359551B (es) 2009-11-24 2018-10-02 Medimmune Ltd Agentes de union diana contra b7-h1.
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
EP2721068B1 (en) * 2011-06-17 2018-12-05 Novo Nordisk A/S Selective elimination of erosive cells
SG10201606284UA (en) 2011-08-01 2016-09-29 Genentech Inc Methods Of Treating Cancer Using Pd-1 Axis Binding Antagonists And Mek Inhibitors
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
WO2016032334A1 (en) 2014-08-28 2016-03-03 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
ES2742456T3 (es) 2014-09-16 2020-02-14 Innate Pharma Regímenes de tratamiento utilizando anticuerpos anti-NKG2A
KR102543739B1 (ko) 2014-09-16 2023-06-16 이나뜨 파르마 에스.에이. 림프구에서의 억제 경로의 중화
WO2016062851A1 (en) 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
CA3012055A1 (en) 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes

Also Published As

Publication number Publication date
CN107001466A (zh) 2017-08-01
ES2825576T3 (es) 2021-05-17
SG10202008228XA (en) 2020-09-29
KR20170067732A (ko) 2017-06-16
BR112017005178A2 (pt) 2018-03-06
ZA201702642B (en) 2018-08-29
SG11201701340RA (en) 2017-03-30
EP3799885A1 (en) 2021-04-07
KR102543739B1 (ko) 2023-06-16
RS60935B1 (sr) 2020-11-30
IL250587B (en) 2021-12-01
US20170291947A1 (en) 2017-10-12
CA2957491A1 (en) 2016-03-24
CN113929782B (zh) 2024-06-21
KR20230088521A (ko) 2023-06-19
EP4368205A1 (en) 2024-05-15
AU2015316991B2 (en) 2021-04-01
EP3193931A1 (en) 2017-07-26
LT3193931T (lt) 2020-11-10
HRP20201656T1 (hr) 2021-03-05
US10711063B2 (en) 2020-07-14
CY1123827T1 (el) 2022-03-24
JP6767362B2 (ja) 2020-10-14
PL3193931T3 (pl) 2021-03-08
CN113929782A (zh) 2022-01-14
MX2017003303A (es) 2017-08-04
CN107001466B (zh) 2021-10-26
RU2734771C2 (ru) 2020-10-23
RU2017105118A3 (da) 2019-04-25
HUE051193T2 (hu) 2021-03-01
US11572410B2 (en) 2023-02-07
RU2017105118A (ru) 2018-10-17
PT3193931T (pt) 2020-10-23
JP2020147572A (ja) 2020-09-17
JP2017530119A (ja) 2017-10-12
NZ729207A (en) 2021-08-27
AU2015316991A1 (en) 2017-03-09
EP3193931B1 (en) 2020-08-05
WO2016041945A1 (en) 2016-03-24
US20230235060A1 (en) 2023-07-27
US20200332008A1 (en) 2020-10-22
SI3193931T1 (sl) 2020-12-31
IL250587A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
DK3193931T3 (da) Neutralisering af hæmmende veje i lymfocytter
DK3405495T3 (da) Neutralisering af hæmmende veje i lymfocytter
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3197883T3 (da) Hidtil ukendte forbindelser
MA44474A (fr) Nouveaux inhibiteurs de la ferroportine
DK3116533T3 (da) Deletion af dystrophingenexon under anvendelse af genmanipulerede nukleaser
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
DK3149124T3 (da) Anvendelse af lavmolekylære imid-holdige kvaternære ammoniumsalte
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3307267T3 (da) Behandling af multipel sklerose
DK3166911T3 (da) Inkorporering af biologiske midler i gødning
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
MA41266A (fr) Cataplasme
DK3418273T3 (da) Derivater af flavagliner
DK3442558T3 (da) Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis
DK3018383T3 (da) Afslutning af styrkeelementer i dybhavskabler
DK3200783T3 (da) Behandling af erytromelalgi
DK3155422T4 (da) Demaskering af endotoksiner i opløsning
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme